Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crisantaspase - Jazz Pharmaceuticals

Next Previous
X
Search
Drug Profile

Crisantaspase - Jazz Pharmaceuticals

Alternative Names: E. chrisanthemi L-asparaginase - EUSA; Asparaginase Erwinia chrysanthemi; E chrisanthemi L asparaginase; Erwina chrisanthemi L-asparaginase; ERWINASE; Erwinase; Erwinaze; Erwinia asparaginase; Erwinia L-asparaginase - EUSA; OP-01

Latest Information Update: 17 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Health Protection Agency
  • Developer EUSA Pharma; Jazz Pharmaceuticals plc; Ohara Pharmaceutical
  • Class Amidohydrolases; Antineoplastics; Cytostatics
  • Mechanism of Action Asparaginase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Registered Lymphoma

Most Recent Events

  • 06 Feb 2024 Registered for Precursor cell lymphoblastic leukaemia-lymphoma in Australia (IM)
  • 06 Feb 2024 Registered for Precursor cell lymphoblastic leukaemia-lymphoma in Australia (IV)
  • 20 Sep 2021 Porton Biopharma requests marketing approval of a BLA for Erwinaze®, which is currently under FDA review

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top